Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verona Pharma PLC VRNA

Healthcare
Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and selective, dual phosphodiesterase 3 and 4 (PDE3 and PDE4) inhibitor. This dual... see more

Recent & Breaking News (NDAQ:VRNA)

Verona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment

GlobeNewswire October 31, 2018

Verona Pharma to Announce Interim Results for Nine Months Ended September 30, 2018 and Provide Clinical Development Update

GlobeNewswire October 30, 2018

Data from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis Presented at North American Cystic Fibrosis Conference

GlobeNewswire October 26, 2018

Verona Pharma to Host Investor & Analyst R&D Forum on October 12, 2018

GlobeNewswire September 27, 2018

Verona Pharma to Host Conference Call to Review Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD Presented at European Respiratory Society International Congress

GlobeNewswire September 13, 2018

Verona Pharma to Present Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD at European Respiratory Society International Congress

GlobeNewswire September 12, 2018

Verona Pharma Announces Publication of Key Paper on RPL554 in COPD in the European Respiratory Journal

GlobeNewswire September 6, 2018

Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2018

GlobeNewswire August 7, 2018

Verona Pharma Initiates Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment

Hugin August 1, 2018

Verona Pharma plc : Notice of Results

Hugin July 26, 2018

Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2018 and Provide Clinical Development Update

GlobeNewswire July 26, 2018

Verona Pharma to Present at 2018 Wedbush PacGrow Healthcare Conference

Hugin July 24, 2018

Verona Pharma plc : Result of General Meeting of Shareholders

Hugin June 26, 2018

Verona Pharma's Shelf Registration Statement declared effective by SEC

Hugin June 4, 2018

Verona Pharma plc : Block Listing Update

Hugin May 31, 2018

Verona Pharma to Present at Upcoming Investor Conferences

Hugin May 30, 2018

Verona Pharma Files Shelf Registration Statement with SEC

Hugin May 23, 2018

Verona Pharma Presented Clinical Data at ATS 2018 that Further Highlights RPL554 as a First-in-Class Treatment for COPD

Hugin May 22, 2018

Verona Pharma plc : Miscellaneous

Hugin May 9, 2018

Verona Pharma to Present Clinical Trial Data of RPL554 for COPD Maintenance Treatment at American Thoracic Society 2018 International Conference

GlobeNewswire May 9, 2018